Furthermore, we demonstrate that tumors with low ZMYND11 expression exhibit enhanced sensitive to inhibitors of the type II arginine methyltransferase PRMT5, highlighting a potential therapeutic avenue for targeting cancers with ZMYND11 dysregulation. The gene discussed is PRMT5; the disease is cancer.